JP2010528644A - 薬物の代謝及び毒性を評価するためのトランスジェニック動物 - Google Patents
薬物の代謝及び毒性を評価するためのトランスジェニック動物 Download PDFInfo
- Publication number
- JP2010528644A JP2010528644A JP2010510871A JP2010510871A JP2010528644A JP 2010528644 A JP2010528644 A JP 2010528644A JP 2010510871 A JP2010510871 A JP 2010510871A JP 2010510871 A JP2010510871 A JP 2010510871A JP 2010528644 A JP2010528644 A JP 2010528644A
- Authority
- JP
- Japan
- Prior art keywords
- human
- animal
- tissue
- mouse
- dna sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241001465754 Metazoa Species 0.000 title claims abstract description 250
- 230000009261 transgenic effect Effects 0.000 title claims abstract description 107
- 230000036267 drug metabolism Effects 0.000 title claims abstract description 61
- 230000001988 toxicity Effects 0.000 title claims description 36
- 231100000419 toxicity Toxicity 0.000 title claims description 36
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 324
- 108091028043 Nucleic acid sequence Proteins 0.000 claims abstract description 297
- 230000014509 gene expression Effects 0.000 claims abstract description 244
- 101100187477 Homo sapiens NR1I2 gene Proteins 0.000 claims abstract description 80
- 239000003814 drug Substances 0.000 claims description 296
- 229940079593 drug Drugs 0.000 claims description 296
- 108010001511 Pregnane X Receptor Proteins 0.000 claims description 184
- 108090000790 Enzymes Proteins 0.000 claims description 140
- 102000004190 Enzymes Human genes 0.000 claims description 135
- 230000000694 effects Effects 0.000 claims description 127
- 108091023040 Transcription factor Proteins 0.000 claims description 119
- 102000040945 Transcription factor Human genes 0.000 claims description 115
- 238000000034 method Methods 0.000 claims description 115
- 230000008685 targeting Effects 0.000 claims description 103
- 102000004169 proteins and genes Human genes 0.000 claims description 95
- 230000006698 induction Effects 0.000 claims description 83
- 108010078791 Carrier Proteins Proteins 0.000 claims description 82
- 230000001105 regulatory effect Effects 0.000 claims description 76
- 108010081668 Cytochrome P-450 CYP3A Proteins 0.000 claims description 72
- 102000004328 Cytochrome P-450 CYP3A Human genes 0.000 claims description 71
- 101100114688 Mus musculus Cyp3a11 gene Proteins 0.000 claims description 71
- 101100114680 Rattus norvegicus Cyp3a2 gene Proteins 0.000 claims description 66
- JQXXHWHPUNPDRT-WLSIYKJHSA-N rifampicin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C([O-])=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CC[NH+](C)CC1 JQXXHWHPUNPDRT-WLSIYKJHSA-N 0.000 claims description 66
- 229960001225 rifampicin Drugs 0.000 claims description 66
- 150000001875 compounds Chemical class 0.000 claims description 63
- 238000003556 assay Methods 0.000 claims description 57
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims description 55
- 102000002004 Cytochrome P-450 Enzyme System Human genes 0.000 claims description 54
- 108010015742 Cytochrome P-450 Enzyme System Proteins 0.000 claims description 54
- 229960003957 dexamethasone Drugs 0.000 claims description 54
- 230000004060 metabolic process Effects 0.000 claims description 48
- 239000013598 vector Substances 0.000 claims description 45
- 238000011830 transgenic mouse model Methods 0.000 claims description 44
- 230000001404 mediated effect Effects 0.000 claims description 41
- BAFKRPOFIYPKBQ-UHFFFAOYSA-N 3,5-dichloro-2-[4-(3,5-dichloropyridin-2-yl)oxyphenoxy]pyridine Chemical compound ClC1=CC(Cl)=CN=C1OC(C=C1)=CC=C1OC1=NC=C(Cl)C=C1Cl BAFKRPOFIYPKBQ-UHFFFAOYSA-N 0.000 claims description 36
- 101000603882 Homo sapiens Nuclear receptor subfamily 1 group I member 3 Proteins 0.000 claims description 34
- 108700008625 Reporter Genes Proteins 0.000 claims description 32
- 239000002299 complementary DNA Substances 0.000 claims description 32
- 241000894007 species Species 0.000 claims description 32
- 108091008053 gene clusters Proteins 0.000 claims description 31
- 108090000743 multidrug resistance protein 3 Proteins 0.000 claims description 31
- 102000004233 multidrug resistance protein 3 Human genes 0.000 claims description 31
- 239000002676 xenobiotic agent Substances 0.000 claims description 31
- ZQWBOKJVVYNKTL-AUEPDCJTSA-N (e)-1-[6-(4-chlorophenyl)imidazo[2,1-b][1,3]thiazol-5-yl]-n-[(3,4-dichlorophenyl)methoxy]methanimine Chemical compound C1=CC(Cl)=CC=C1C1=C(\C=N\OCC=2C=C(Cl)C(Cl)=CC=2)N2C=CSC2=N1 ZQWBOKJVVYNKTL-AUEPDCJTSA-N 0.000 claims description 29
- 108010047230 Member 1 Subfamily B ATP Binding Cassette Transporter Proteins 0.000 claims description 28
- 108700024394 Exon Proteins 0.000 claims description 27
- 101100187479 Mus musculus Nr1i2 gene Proteins 0.000 claims description 27
- 150000007523 nucleic acids Chemical class 0.000 claims description 27
- 102100033350 ATP-dependent translocase ABCB1 Human genes 0.000 claims description 26
- 102000014914 Carrier Proteins Human genes 0.000 claims description 25
- 238000012217 deletion Methods 0.000 claims description 25
- 230000037430 deletion Effects 0.000 claims description 25
- 238000013519 translation Methods 0.000 claims description 22
- 108020004414 DNA Proteins 0.000 claims description 21
- 102100029363 Cytochrome P450 2C19 Human genes 0.000 claims description 19
- 102000023984 PPAR alpha Human genes 0.000 claims description 19
- 108010012052 cytochrome P-450 CYP2C subfamily Proteins 0.000 claims description 19
- 108091008725 peroxisome proliferator-activated receptors alpha Proteins 0.000 claims description 19
- 102000039446 nucleic acids Human genes 0.000 claims description 18
- 108020004707 nucleic acids Proteins 0.000 claims description 18
- 108010000543 Cytochrome P-450 CYP2C9 Proteins 0.000 claims description 17
- 102000002269 Cytochrome P-450 CYP2C9 Human genes 0.000 claims description 17
- 108010029485 Protein Isoforms Proteins 0.000 claims description 17
- 102000001708 Protein Isoforms Human genes 0.000 claims description 17
- VSBHRRMYCDQLJF-ZDNYCOCVSA-N pregnenolone 16alpha-carbonitrile Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@@H](C#N)[C@H](C(=O)C)[C@@]1(C)CC2 VSBHRRMYCDQLJF-ZDNYCOCVSA-N 0.000 claims description 17
- 108010001237 Cytochrome P-450 CYP2D6 Proteins 0.000 claims description 16
- 102100021704 Cytochrome P450 2D6 Human genes 0.000 claims description 16
- 108091092195 Intron Proteins 0.000 claims description 15
- 101000745711 Homo sapiens Cytochrome P450 3A4 Proteins 0.000 claims description 14
- 101000858032 Mus musculus Coxsackievirus and adenovirus receptor homolog Proteins 0.000 claims description 14
- 101001124276 Mus musculus Nuclear receptor subfamily 1 group I member 3 Proteins 0.000 claims description 14
- 101000896586 Homo sapiens Cytochrome P450 2D6 Proteins 0.000 claims description 13
- 101000896576 Homo sapiens Putative cytochrome P450 2D7 Proteins 0.000 claims description 13
- 101150055214 cyp1a1 gene Proteins 0.000 claims description 13
- 230000000717 retained effect Effects 0.000 claims description 13
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 12
- 102100021702 Putative cytochrome P450 2D7 Human genes 0.000 claims description 12
- 241000283984 Rodentia Species 0.000 claims description 12
- 102000044284 human CYP3A4 Human genes 0.000 claims description 12
- 101100168383 Rattus norvegicus Cyp2c11 gene Proteins 0.000 claims description 11
- 206010019851 Hepatotoxicity Diseases 0.000 claims description 10
- 101001017818 Homo sapiens ATP-dependent translocase ABCB1 Proteins 0.000 claims description 9
- 231100000304 hepatotoxicity Toxicity 0.000 claims description 9
- 230000007686 hepatotoxicity Effects 0.000 claims description 9
- 102000053576 human ABCB1 Human genes 0.000 claims description 9
- 108010074922 Cytochrome P-450 CYP1A2 Proteins 0.000 claims description 7
- 102000008144 Cytochrome P-450 CYP1A2 Human genes 0.000 claims description 7
- 108010020070 Cytochrome P-450 CYP2B6 Proteins 0.000 claims description 7
- 102000009666 Cytochrome P-450 CYP2B6 Human genes 0.000 claims description 7
- 102100024889 Cytochrome P450 2E1 Human genes 0.000 claims description 7
- 102000005720 Glutathione transferase Human genes 0.000 claims description 7
- 108010070675 Glutathione transferase Proteins 0.000 claims description 7
- 101100329196 Homo sapiens CYP2D6 gene Proteins 0.000 claims description 7
- 101000957383 Homo sapiens Cytochrome P450 2B6 Proteins 0.000 claims description 7
- 238000012239 gene modification Methods 0.000 claims description 7
- -1 CYP2B10 Proteins 0.000 claims description 6
- 108010074918 Cytochrome P-450 CYP1A1 Proteins 0.000 claims description 6
- 102000008142 Cytochrome P-450 CYP1A1 Human genes 0.000 claims description 6
- 101000841498 Homo sapiens UDP-glucuronosyltransferase 1A1 Proteins 0.000 claims description 6
- 101100114686 Rattus norvegicus Cyp3a9 gene Proteins 0.000 claims description 6
- 150000001413 amino acids Chemical group 0.000 claims description 6
- 108010000561 Cytochrome P-450 CYP2C8 Proteins 0.000 claims description 5
- 102100029359 Cytochrome P450 2C8 Human genes 0.000 claims description 5
- 101000919359 Homo sapiens Cytochrome P450 2C9 Proteins 0.000 claims description 5
- 102000007990 Organic Anion Transporters Human genes 0.000 claims description 5
- 108010089503 Organic Anion Transporters Proteins 0.000 claims description 5
- 102100029152 UDP-glucuronosyltransferase 1A1 Human genes 0.000 claims description 5
- 229960004022 clotrimazole Drugs 0.000 claims description 5
- VNFPBHJOKIVQEB-UHFFFAOYSA-N clotrimazole Chemical compound ClC1=CC=CC=C1C(N1C=NC=C1)(C=1C=CC=CC=1)C1=CC=CC=C1 VNFPBHJOKIVQEB-UHFFFAOYSA-N 0.000 claims description 5
- 230000000295 complement effect Effects 0.000 claims description 5
- 101150117450 CYP1A2 gene Proteins 0.000 claims description 4
- 108010026925 Cytochrome P-450 CYP2C19 Proteins 0.000 claims description 4
- 108010001202 Cytochrome P-450 CYP2E1 Proteins 0.000 claims description 4
- 101000741788 Homo sapiens Peroxisome proliferator-activated receptor alpha Proteins 0.000 claims description 4
- 101100385057 Mus musculus Cyp3a25 gene Proteins 0.000 claims description 4
- 101150058049 car gene Proteins 0.000 claims description 4
- 230000005017 genetic modification Effects 0.000 claims description 4
- 235000013617 genetically modified food Nutrition 0.000 claims description 4
- 102000048369 human CYP2C9 Human genes 0.000 claims description 4
- 238000011144 upstream manufacturing Methods 0.000 claims description 4
- 102100022595 Broad substrate specificity ATP-binding cassette transporter ABCG2 Human genes 0.000 claims description 3
- 102100038739 Cytochrome P450 2B6 Human genes 0.000 claims description 3
- 102000016354 Glucuronosyltransferase Human genes 0.000 claims description 3
- 108010092364 Glucuronosyltransferase Proteins 0.000 claims description 3
- 101000909131 Homo sapiens Cytochrome P450 2E1 Proteins 0.000 claims description 3
- 102000004855 Multi drug resistance-associated proteins Human genes 0.000 claims description 3
- 108090001099 Multi drug resistance-associated proteins Proteins 0.000 claims description 3
- 102000014842 Multidrug resistance proteins Human genes 0.000 claims description 3
- 108050005144 Multidrug resistance proteins Proteins 0.000 claims description 3
- 108010087367 P-glycoprotein 2 Proteins 0.000 claims description 3
- 108020002494 acetyltransferase Proteins 0.000 claims description 3
- 102000005421 acetyltransferase Human genes 0.000 claims description 3
- 238000010348 incorporation Methods 0.000 claims description 3
- 108010090306 Member 2 Subfamily G ATP Binding Cassette Transporter Proteins 0.000 claims description 2
- 102100021339 Multidrug resistance-associated protein 1 Human genes 0.000 claims description 2
- 108010066052 multidrug resistance-associated protein 1 Proteins 0.000 claims description 2
- 102000047894 human CYP2B6 Human genes 0.000 claims 4
- 102000054928 human CYP3A Human genes 0.000 claims 3
- 108700021672 human CYP3A Proteins 0.000 claims 3
- 101000690540 Homo sapiens Aryl hydrocarbon receptor Proteins 0.000 claims 2
- 101000941690 Homo sapiens Cytochrome P450 1A1 Proteins 0.000 claims 2
- 101000855342 Homo sapiens Cytochrome P450 1A2 Proteins 0.000 claims 2
- 101000672024 Homo sapiens UDP-glucose:glycoprotein glucosyltransferase 1 Proteins 0.000 claims 2
- 101000690535 Mus musculus Aryl hydrocarbon receptor Proteins 0.000 claims 2
- 101100114663 Mus musculus Cyp2c55 gene Proteins 0.000 claims 2
- 101000741778 Mus musculus Peroxisome proliferator-activated receptor alpha Proteins 0.000 claims 2
- 102000052268 human CYP1A1 Human genes 0.000 claims 2
- 102000057459 human CYP1A2 Human genes 0.000 claims 2
- 102100025278 Coxsackievirus and adenovirus receptor Human genes 0.000 claims 1
- 101100131294 Homo sapiens ABCC2 gene Proteins 0.000 claims 1
- 101100001274 Homo sapiens AHR gene Proteins 0.000 claims 1
- 101000823298 Homo sapiens Broad substrate specificity ATP-binding cassette transporter ABCG2 Proteins 0.000 claims 1
- 101000858031 Homo sapiens Coxsackievirus and adenovirus receptor Proteins 0.000 claims 1
- 101100316023 Mus musculus Uggt1 gene Proteins 0.000 claims 1
- 101100371717 Mus musculus Ugt1a1 gene Proteins 0.000 claims 1
- 101100371719 Mus musculus Ugt1a2 gene Proteins 0.000 claims 1
- 101100048299 Mus musculus Ugt1a6 gene Proteins 0.000 claims 1
- 102000000804 Pregnane X Receptor Human genes 0.000 claims 1
- 101710148271 UDP-glucose:glycoprotein glucosyltransferase 1 Proteins 0.000 claims 1
- 102000054223 human PPARA Human genes 0.000 claims 1
- 238000001727 in vivo Methods 0.000 abstract description 22
- 230000033228 biological regulation Effects 0.000 abstract description 14
- 102000003839 Human Proteins Human genes 0.000 abstract description 11
- 108090000144 Human Proteins Proteins 0.000 abstract description 11
- 238000004519 manufacturing process Methods 0.000 abstract description 11
- 235000021120 animal protein Nutrition 0.000 abstract description 2
- 241000699670 Mus sp. Species 0.000 description 468
- 210000004027 cell Anatomy 0.000 description 199
- 102100038494 Nuclear receptor subfamily 1 group I member 2 Human genes 0.000 description 171
- 210000001519 tissue Anatomy 0.000 description 164
- 241000699666 Mus <mouse, genus> Species 0.000 description 157
- 108010029704 Constitutive Androstane Receptor Proteins 0.000 description 98
- 102100038512 Nuclear receptor subfamily 1 group I member 3 Human genes 0.000 description 97
- 235000018102 proteins Nutrition 0.000 description 82
- 210000004185 liver Anatomy 0.000 description 79
- 101100440875 Mus musculus Cyp2b10 gene Proteins 0.000 description 58
- 241000282412 Homo Species 0.000 description 50
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 44
- 108020004999 messenger RNA Proteins 0.000 description 43
- 238000011577 humanized mouse model Methods 0.000 description 35
- 101150053185 P450 gene Proteins 0.000 description 31
- 238000004458 analytical method Methods 0.000 description 30
- 238000001262 western blot Methods 0.000 description 30
- 230000004044 response Effects 0.000 description 29
- SIDLHXXVIBTSJZ-UHFFFAOYSA-N 7-phenylmethoxyquinoline Chemical compound C=1C=C2C=CC=NC2=CC=1OCC1=CC=CC=C1 SIDLHXXVIBTSJZ-UHFFFAOYSA-N 0.000 description 28
- 239000000411 inducer Substances 0.000 description 28
- 238000011282 treatment Methods 0.000 description 26
- 238000002474 experimental method Methods 0.000 description 23
- 210000001853 liver microsome Anatomy 0.000 description 23
- 229960003604 testosterone Drugs 0.000 description 23
- 230000002034 xenobiotic effect Effects 0.000 description 21
- 238000005805 hydroxylation reaction Methods 0.000 description 20
- 230000001965 increasing effect Effects 0.000 description 20
- 230000006870 function Effects 0.000 description 18
- 230000037353 metabolic pathway Effects 0.000 description 18
- 230000006798 recombination Effects 0.000 description 17
- 210000004102 animal cell Anatomy 0.000 description 16
- DDBREPKUVSBGFI-UHFFFAOYSA-N phenobarbital Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NC(=O)NC1=O DDBREPKUVSBGFI-UHFFFAOYSA-N 0.000 description 16
- 229960002695 phenobarbital Drugs 0.000 description 16
- 241000699660 Mus musculus Species 0.000 description 15
- 230000008901 benefit Effects 0.000 description 15
- 238000012360 testing method Methods 0.000 description 15
- 108010045510 NADPH-Ferrihemoprotein Reductase Proteins 0.000 description 14
- 230000009471 action Effects 0.000 description 13
- 230000037396 body weight Effects 0.000 description 13
- 238000001952 enzyme assay Methods 0.000 description 13
- 230000002503 metabolic effect Effects 0.000 description 13
- 238000005215 recombination Methods 0.000 description 13
- 108010088751 Albumins Proteins 0.000 description 12
- 102000009027 Albumins Human genes 0.000 description 12
- 238000009826 distribution Methods 0.000 description 12
- 230000037361 pathway Effects 0.000 description 12
- 238000011813 knockout mouse model Methods 0.000 description 11
- 239000003446 ligand Substances 0.000 description 11
- 210000001671 embryonic stem cell Anatomy 0.000 description 10
- 239000000758 substrate Substances 0.000 description 10
- 102000018075 Subfamily B ATP Binding Cassette Transporter Human genes 0.000 description 9
- 108010091105 Subfamily B ATP Binding Cassette Transporter Proteins 0.000 description 9
- 238000010171 animal model Methods 0.000 description 9
- 210000001035 gastrointestinal tract Anatomy 0.000 description 9
- 239000002207 metabolite Substances 0.000 description 9
- 238000013518 transcription Methods 0.000 description 9
- 230000035897 transcription Effects 0.000 description 9
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 8
- 108010082126 Alanine transaminase Proteins 0.000 description 8
- 238000000692 Student's t-test Methods 0.000 description 8
- 108700019146 Transgenes Proteins 0.000 description 8
- 210000002459 blastocyst Anatomy 0.000 description 8
- 210000003494 hepatocyte Anatomy 0.000 description 8
- 210000005260 human cell Anatomy 0.000 description 8
- 238000010200 validation analysis Methods 0.000 description 8
- YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 7
- 241000124008 Mammalia Species 0.000 description 7
- 239000002131 composite material Substances 0.000 description 7
- 210000000936 intestine Anatomy 0.000 description 7
- 238000005259 measurement Methods 0.000 description 7
- 239000002773 nucleotide Substances 0.000 description 7
- 125000003729 nucleotide group Chemical group 0.000 description 7
- 230000035945 sensitivity Effects 0.000 description 7
- 210000000813 small intestine Anatomy 0.000 description 7
- 238000010561 standard procedure Methods 0.000 description 7
- 230000022814 xenobiotic metabolic process Effects 0.000 description 7
- 101100309386 Mus musculus Slc35a2 gene Proteins 0.000 description 6
- 229930193140 Neomycin Natural products 0.000 description 6
- 238000002105 Southern blotting Methods 0.000 description 6
- 101150060067 Uggt1 gene Proteins 0.000 description 6
- 101150115356 Ugt1a1 gene Proteins 0.000 description 6
- 101150064302 Ugt1a2 gene Proteins 0.000 description 6
- 101150068269 Ugt1a6 gene Proteins 0.000 description 6
- 238000013459 approach Methods 0.000 description 6
- 210000004436 artificial bacterial chromosome Anatomy 0.000 description 6
- 230000008499 blood brain barrier function Effects 0.000 description 6
- 210000001218 blood-brain barrier Anatomy 0.000 description 6
- 230000001276 controlling effect Effects 0.000 description 6
- 230000002950 deficient Effects 0.000 description 6
- 238000011161 development Methods 0.000 description 6
- 230000002068 genetic effect Effects 0.000 description 6
- 229960004927 neomycin Drugs 0.000 description 6
- 239000000523 sample Substances 0.000 description 6
- 238000012216 screening Methods 0.000 description 6
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 6
- 238000001890 transfection Methods 0.000 description 6
- 230000032258 transport Effects 0.000 description 6
- WOVKYSAHUYNSMH-RRKCRQDMSA-N 5-bromodeoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-RRKCRQDMSA-N 0.000 description 5
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 5
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 5
- 238000011814 C57BL/6N mouse Methods 0.000 description 5
- 206010068051 Chimerism Diseases 0.000 description 5
- 239000012190 activator Substances 0.000 description 5
- 238000009395 breeding Methods 0.000 description 5
- 230000001488 breeding effect Effects 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 238000010586 diagram Methods 0.000 description 5
- 238000004520 electroporation Methods 0.000 description 5
- 238000003028 enzyme activity measurement method Methods 0.000 description 5
- 239000012634 fragment Substances 0.000 description 5
- 108020001507 fusion proteins Proteins 0.000 description 5
- 102000037865 fusion proteins Human genes 0.000 description 5
- 230000006801 homologous recombination Effects 0.000 description 5
- 238000002744 homologous recombination Methods 0.000 description 5
- 206010020718 hyperplasia Diseases 0.000 description 5
- 230000002390 hyperplastic effect Effects 0.000 description 5
- 230000001939 inductive effect Effects 0.000 description 5
- 238000003780 insertion Methods 0.000 description 5
- 230000037431 insertion Effects 0.000 description 5
- 230000000968 intestinal effect Effects 0.000 description 5
- 108020001756 ligand binding domains Proteins 0.000 description 5
- 230000007246 mechanism Effects 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 238000010369 molecular cloning Methods 0.000 description 5
- 238000011002 quantification Methods 0.000 description 5
- 102000005962 receptors Human genes 0.000 description 5
- 108020003175 receptors Proteins 0.000 description 5
- 231100000331 toxic Toxicity 0.000 description 5
- 230000002588 toxic effect Effects 0.000 description 5
- 238000012301 transgenic model Methods 0.000 description 5
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 4
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 4
- 102000011022 Chorionic Gonadotropin Human genes 0.000 description 4
- 108010062540 Chorionic Gonadotropin Proteins 0.000 description 4
- 108091026890 Coding region Proteins 0.000 description 4
- 108010051219 Cre recombinase Proteins 0.000 description 4
- 101000956263 Homo sapiens Uncharacterized protein C19orf48 Proteins 0.000 description 4
- 101100400864 Mus musculus Abcb1a gene Proteins 0.000 description 4
- 101100400865 Mus musculus Abcb1b gene Proteins 0.000 description 4
- 241000283973 Oryctolagus cuniculus Species 0.000 description 4
- 101100400874 Rattus norvegicus Abcb1 gene Proteins 0.000 description 4
- 108010091086 Recombinases Proteins 0.000 description 4
- 102000018120 Recombinases Human genes 0.000 description 4
- 102100038573 Uncharacterized protein C19orf48 Human genes 0.000 description 4
- 238000003149 assay kit Methods 0.000 description 4
- 210000004556 brain Anatomy 0.000 description 4
- 230000000711 cancerogenic effect Effects 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 239000002285 corn oil Substances 0.000 description 4
- 235000005687 corn oil Nutrition 0.000 description 4
- 230000020335 dealkylation Effects 0.000 description 4
- 238000006900 dealkylation reaction Methods 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 229940084986 human chorionic gonadotropin Drugs 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 230000037323 metabolic rate Effects 0.000 description 4
- 230000003228 microsomal effect Effects 0.000 description 4
- 231100000804 nongenotoxic Toxicity 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- 230000001766 physiological effect Effects 0.000 description 4
- 230000035790 physiological processes and functions Effects 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- XCRPPAPDRUBKRJ-UHFFFAOYSA-N quinolin-7-ol Chemical compound C1=CC=NC2=CC(O)=CC=C21 XCRPPAPDRUBKRJ-UHFFFAOYSA-N 0.000 description 4
- 238000003753 real-time PCR Methods 0.000 description 4
- 238000003757 reverse transcription PCR Methods 0.000 description 4
- 230000004622 sleep time Effects 0.000 description 4
- 210000000130 stem cell Anatomy 0.000 description 4
- 230000002103 transcriptional effect Effects 0.000 description 4
- 239000003981 vehicle Substances 0.000 description 4
- 108020005065 3' Flanking Region Proteins 0.000 description 3
- 108020005029 5' Flanking Region Proteins 0.000 description 3
- 101150116544 CYP3A4 gene Proteins 0.000 description 3
- 102000019057 Cytochrome P-450 CYP2C19 Human genes 0.000 description 3
- 108090000143 Mouse Proteins Proteins 0.000 description 3
- 102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 description 3
- 108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 description 3
- 241000288906 Primates Species 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 229940024606 amino acid Drugs 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 231100000315 carcinogenic Toxicity 0.000 description 3
- 210000000170 cell membrane Anatomy 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 3
- 238000012790 confirmation Methods 0.000 description 3
- 230000017858 demethylation Effects 0.000 description 3
- 238000010520 demethylation reaction Methods 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 238000010353 genetic engineering Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 238000012544 monitoring process Methods 0.000 description 3
- 108700028732 mouse CYP3A Proteins 0.000 description 3
- 238000010172 mouse model Methods 0.000 description 3
- 210000002569 neuron Anatomy 0.000 description 3
- 210000004940 nucleus Anatomy 0.000 description 3
- 230000002018 overexpression Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 102100021501 ATP-binding cassette sub-family B member 5 Human genes 0.000 description 2
- 102100026189 Beta-galactosidase Human genes 0.000 description 2
- 206010058941 Bile duct necrosis Diseases 0.000 description 2
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 101150052538 CYP3A5 gene Proteins 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- 206010007269 Carcinogenicity Diseases 0.000 description 2
- 241000700198 Cavia Species 0.000 description 2
- 241000282693 Cercopithecidae Species 0.000 description 2
- 206010061764 Chromosomal deletion Diseases 0.000 description 2
- 208000004752 Cytochrome P-450 Enzyme Inducers Diseases 0.000 description 2
- 241000283086 Equidae Species 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 2
- 101000677872 Homo sapiens ATP-binding cassette sub-family B member 5 Proteins 0.000 description 2
- 108091026898 Leader sequence (mRNA) Proteins 0.000 description 2
- 108700041567 MDR Genes Proteins 0.000 description 2
- 101000640792 Mus musculus UDP-galactose translocator Proteins 0.000 description 2
- 102000007399 Nuclear hormone receptor Human genes 0.000 description 2
- 108020005497 Nuclear hormone receptor Proteins 0.000 description 2
- 238000010222 PCR analysis Methods 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 241000282887 Suidae Species 0.000 description 2
- 108091036066 Three prime untranslated region Proteins 0.000 description 2
- 102000006601 Thymidine Kinase Human genes 0.000 description 2
- 108020004440 Thymidine kinase Proteins 0.000 description 2
- 230000000735 allogeneic effect Effects 0.000 description 2
- 239000000935 antidepressant agent Substances 0.000 description 2
- 229940005513 antidepressants Drugs 0.000 description 2
- 210000001106 artificial yeast chromosome Anatomy 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 108010005774 beta-Galactosidase Proteins 0.000 description 2
- 239000003613 bile acid Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 231100000357 carcinogen Toxicity 0.000 description 2
- 239000003183 carcinogenic agent Substances 0.000 description 2
- 231100000260 carcinogenicity Toxicity 0.000 description 2
- 230000007670 carcinogenicity Effects 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 210000000349 chromosome Anatomy 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 230000001086 cytosolic effect Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 210000004602 germ cell Anatomy 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 230000002440 hepatic effect Effects 0.000 description 2
- 230000033444 hydroxylation Effects 0.000 description 2
- 238000003119 immunoblot Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 230000010354 integration Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 102000003888 major urinary proteins Human genes 0.000 description 2
- 108090000280 major urinary proteins Proteins 0.000 description 2
- 238000010208 microarray analysis Methods 0.000 description 2
- 238000000520 microinjection Methods 0.000 description 2
- 239000002547 new drug Substances 0.000 description 2
- 231100001092 no hepatotoxicity Toxicity 0.000 description 2
- 230000008520 organization Effects 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000001177 retroviral effect Effects 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- 238000003153 stable transfection Methods 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 230000002110 toxicologic effect Effects 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 230000001052 transient effect Effects 0.000 description 2
- 238000003146 transient transfection Methods 0.000 description 2
- 238000011179 visual inspection Methods 0.000 description 2
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 1
- ZQWBOKJVVYNKTL-UHFFFAOYSA-N 1-[6-(4-chlorophenyl)-5-imidazo[2,1-b]thiazolyl]-N-[(3,4-dichlorophenyl)methoxy]methanimine Chemical compound C1=CC(Cl)=CC=C1C1=C(C=NOCC=2C=C(Cl)C(Cl)=CC=2)N2C=CSC2=N1 ZQWBOKJVVYNKTL-UHFFFAOYSA-N 0.000 description 1
- 108020005345 3' Untranslated Regions Proteins 0.000 description 1
- 108020003589 5' Untranslated Regions Proteins 0.000 description 1
- WQVWZPZHJFKZIZ-UHFFFAOYSA-N 7-benzylquinoline Chemical compound C=1C=C2C=CC=NC2=CC=1CC1=CC=CC=C1 WQVWZPZHJFKZIZ-UHFFFAOYSA-N 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- 101710137189 Amyloid-beta A4 protein Proteins 0.000 description 1
- 101710151993 Amyloid-beta precursor protein Proteins 0.000 description 1
- 101100275555 Arabidopsis thaliana CYP19-2 gene Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 101150081058 CPR gene Proteins 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 108010035563 Chloramphenicol O-acetyltransferase Proteins 0.000 description 1
- 206010008635 Cholestasis Diseases 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 101100497958 Crocosmia x crocosmiiflora CYP75B138 gene Proteins 0.000 description 1
- 101150116929 Cyp2c55 gene Proteins 0.000 description 1
- 102000018832 Cytochromes Human genes 0.000 description 1
- 108010052832 Cytochromes Proteins 0.000 description 1
- 101100353003 Dictyostelium discoideum cypB gene Proteins 0.000 description 1
- 238000008789 Direct Bilirubin Methods 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 208000009139 Gilbert Disease Diseases 0.000 description 1
- 208000022412 Gilbert syndrome Diseases 0.000 description 1
- 108010060309 Glucuronidase Proteins 0.000 description 1
- 102000053187 Glucuronidase Human genes 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 102100022057 Hepatocyte nuclear factor 1-alpha Human genes 0.000 description 1
- 102100022054 Hepatocyte nuclear factor 4-alpha Human genes 0.000 description 1
- 101001045751 Homo sapiens Hepatocyte nuclear factor 1-alpha Proteins 0.000 description 1
- 101001045740 Homo sapiens Hepatocyte nuclear factor 4-alpha Proteins 0.000 description 1
- 101000588302 Homo sapiens Nuclear factor erythroid 2-related factor 2 Proteins 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- 101100440863 Mesocricetus auratus CYP2A9 gene Proteins 0.000 description 1
- 102000008109 Mixed Function Oxygenases Human genes 0.000 description 1
- 108010074633 Mixed Function Oxygenases Proteins 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 101100497133 Mus musculus Cyp2d26 gene Proteins 0.000 description 1
- 101100114690 Mus musculus Cyp3a13 gene Proteins 0.000 description 1
- 101100114693 Mus musculus Cyp3a16 gene Proteins 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- 102100031701 Nuclear factor erythroid 2-related factor 2 Human genes 0.000 description 1
- 231100000264 OECD 451 Carcinogenicity Study Toxicity 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 206010035148 Plague Diseases 0.000 description 1
- 108091008109 Pseudogenes Proteins 0.000 description 1
- 102000057361 Pseudogenes Human genes 0.000 description 1
- 108091027981 Response element Proteins 0.000 description 1
- 230000018199 S phase Effects 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 101100276526 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) CPR2 gene Proteins 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 238000008050 Total Bilirubin Reagent Methods 0.000 description 1
- 206010070863 Toxicity to various agents Diseases 0.000 description 1
- 108700009124 Transcription Initiation Site Proteins 0.000 description 1
- 102000004357 Transferases Human genes 0.000 description 1
- 108090000992 Transferases Proteins 0.000 description 1
- 108010075920 UDP-galactose translocator Proteins 0.000 description 1
- 101710205316 UDP-glucuronosyltransferase 1A1 Proteins 0.000 description 1
- 241000607479 Yersinia pestis Species 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 230000002730 additional effect Effects 0.000 description 1
- 210000004504 adult stem cell Anatomy 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003524 antilipemic agent Substances 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- HNYOPLTXPVRDBG-UHFFFAOYSA-M barbiturate Chemical compound O=C1CC(=O)[N-]C(=O)N1 HNYOPLTXPVRDBG-UHFFFAOYSA-M 0.000 description 1
- 229940125717 barbiturate Drugs 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 231100000359 cholestasis Toxicity 0.000 description 1
- 230000007870 cholestasis Effects 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 238000012733 comparative method Methods 0.000 description 1
- 230000001268 conjugating effect Effects 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 101150089050 cyp2 gene Proteins 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 238000007877 drug screening Methods 0.000 description 1
- 238000003255 drug test Methods 0.000 description 1
- 230000008406 drug-drug interaction Effects 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 239000003256 environmental substance Substances 0.000 description 1
- 230000001973 epigenetic effect Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 230000030279 gene silencing Effects 0.000 description 1
- 230000004034 genetic regulation Effects 0.000 description 1
- 230000037442 genomic alteration Effects 0.000 description 1
- 238000003205 genotyping method Methods 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 231100000334 hepatotoxic Toxicity 0.000 description 1
- 230000003082 hepatotoxic effect Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000000366 juvenile effect Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 108010006109 methoxyresorufin-O-demethylase Proteins 0.000 description 1
- 238000002493 microarray Methods 0.000 description 1
- 229960003793 midazolam Drugs 0.000 description 1
- DDLIGBOFAVUZHB-UHFFFAOYSA-N midazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NC=C2CN=C1C1=CC=CC=C1F DDLIGBOFAVUZHB-UHFFFAOYSA-N 0.000 description 1
- 231100000219 mutagenic Toxicity 0.000 description 1
- 230000003505 mutagenic effect Effects 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 239000003176 neuroleptic agent Substances 0.000 description 1
- 108020004017 nuclear receptors Proteins 0.000 description 1
- 150000002891 organic anions Chemical class 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- 230000002974 pharmacogenomic effect Effects 0.000 description 1
- 238000001050 pharmacotherapy Methods 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 230000006461 physiological response Effects 0.000 description 1
- 230000003169 placental effect Effects 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 210000003240 portal vein Anatomy 0.000 description 1
- 230000029279 positive regulation of transcription, DNA-dependent Effects 0.000 description 1
- 230000001124 posttranscriptional effect Effects 0.000 description 1
- 101150031304 ppi1 gene Proteins 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000004853 protein function Effects 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 239000002469 receptor inverse agonist Substances 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 230000007363 regulatory process Effects 0.000 description 1
- HSSLDCABUXLXKM-UHFFFAOYSA-N resorufin Chemical compound C1=CC(=O)C=C2OC3=CC(O)=CC=C3N=C21 HSSLDCABUXLXKM-UHFFFAOYSA-N 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 238000007423 screening assay Methods 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 210000001082 somatic cell Anatomy 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000003390 teratogenic effect Effects 0.000 description 1
- 229940124598 therapeutic candidate Drugs 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 231100000048 toxicity data Toxicity 0.000 description 1
- 231100000723 toxicological property Toxicity 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 231100000041 toxicology testing Toxicity 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000012451 transgenic animal system Methods 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000009452 underexpressoin Effects 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
- A01K67/0276—Knock-out vertebrates
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
- A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
- C07K14/721—Steroid/thyroid hormone superfamily, e.g. GR, EcR, androgen receptor, oestrogen receptor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/795—Porphyrin- or corrin-ring-containing peptides
- C07K14/80—Cytochromes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2207/00—Modified animals
- A01K2207/15—Humanized animals
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/0393—Animal model comprising a reporter system for screening tests
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Environmental Sciences (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Biodiversity & Conservation Biology (AREA)
- Animal Husbandry (AREA)
- Animal Behavior & Ethology (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Endocrinology (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Toxicology (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Immunology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11/757,972 US7759541B2 (en) | 2004-12-13 | 2007-06-04 | Transgenic animals for assessing drug metabolism and toxicity |
| PCT/GB2008/001897 WO2008149080A1 (en) | 2007-06-04 | 2008-06-04 | Transgenic animals for assessing drug metabolism and toxicity |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010528644A true JP2010528644A (ja) | 2010-08-26 |
| JP2010528644A5 JP2010528644A5 (enExample) | 2011-07-14 |
Family
ID=39698732
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010510871A Pending JP2010528644A (ja) | 2007-06-04 | 2008-06-04 | 薬物の代謝及び毒性を評価するためのトランスジェニック動物 |
Country Status (8)
| Country | Link |
|---|---|
| US (3) | US7759541B2 (enExample) |
| EP (1) | EP2173160A1 (enExample) |
| JP (1) | JP2010528644A (enExample) |
| AU (1) | AU2008259618A1 (enExample) |
| CA (1) | CA2688438A1 (enExample) |
| IL (1) | IL202127A0 (enExample) |
| IN (1) | IN2009DN07390A (enExample) |
| WO (1) | WO2008149080A1 (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2014526932A (ja) * | 2011-08-26 | 2014-10-09 | オレア メディカル エスアエス | 動脈／組織／静脈の動態系の注目量を推定するシステムおよび方法 |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7759541B2 (en) | 2004-12-13 | 2010-07-20 | Iti Life Sciences | Transgenic animals for assessing drug metabolism and toxicity |
| EP2218786B1 (en) * | 2007-11-14 | 2013-09-18 | National University Corporation Tottori University | Mammalian artificial chromosome vector comprising human cytochrome p450 gene (cluster), and non-human mammalian animal retaining the same |
| EP3417701B1 (en) | 2009-10-06 | 2021-12-15 | Regeneron Pharmaceuticals, Inc. | Genetically modified mice and engraftment |
| CN102286398B (zh) * | 2010-06-21 | 2014-06-04 | 中国科学院上海生命科学研究院 | 一种生产高活性和高纯度利福霉素sv的方法 |
| US20120023599A1 (en) * | 2010-07-23 | 2012-01-26 | Sigma-Aldrich Co. | Genome editing of cytochrome p450 in animals |
| RU2577978C2 (ru) | 2011-02-15 | 2016-03-20 | Ридженерон Фармасьютикалз, Инк. | Гуманизированные m-csf мыши |
| RU2751240C2 (ru) * | 2011-10-28 | 2021-07-12 | Регенерон Фармасьютикалс, Инк. | Гуманизированные il-6 и рецептор il-6 |
| US8962913B2 (en) | 2012-06-18 | 2015-02-24 | Regeneron Pharmaceuticals, Inc. | Humanized IL-7 rodents |
| NZ746089A (en) | 2012-09-07 | 2020-05-29 | Institute For Res In Biomedicine Irb | Genetically modified non-human animals and methods of use thereof |
| ES2748662T3 (es) | 2012-11-05 | 2020-03-17 | Institute For Res In Biomedicine Irb | Roedores inmunodeficientes modificados genéticamente y métodos de uso de los mismos |
| US20140273031A1 (en) * | 2013-03-15 | 2014-09-18 | The Cleveland Clinic Foundation | In-vitro method for monoclonal antibody production |
| TR201904342T4 (tr) | 2013-10-15 | 2019-05-21 | Regeneron Pharma | Hümani̇ze il-15 hayvanlar |
| EP3430898A1 (en) * | 2013-11-19 | 2019-01-23 | Regeneron Pharmaceuticals, Inc. | Non-human animals having a humanized a proliferation-inducing ligand gene |
| EP3071024B1 (en) * | 2013-11-19 | 2018-09-05 | Regeneron Pharmaceuticals, Inc. | Non-human animals having a humanized b-cell activating factor gene |
| US9665718B2 (en) | 2014-03-14 | 2017-05-30 | International Business Machines Corporation | Correlating a task with commands to perform a change ticket in an IT system |
| KR102821645B1 (ko) | 2014-05-19 | 2025-06-19 | 리제너론 파마슈티칼스 인코포레이티드 | 인간 epo를 발현하는 유전자 변형된 비-인간 동물 |
| SG10202103445QA (en) | 2015-04-13 | 2021-05-28 | Regeneron Pharma | Humanized sirpa-il15 knockin mice and methods of use thereof |
| JP2019524077A (ja) | 2016-06-27 | 2019-09-05 | ベイラー カレッジ オブ メディスンＢａｙｌｏｒ Ｃｏｌｌｅｇｅ Ｏｆ Ｍｅｄｉｃｉｎｅ | Ｐ４５０オキシドレダクターゼ欠損を有するヒト肝臓キメラ非ヒト動物およびそれを使用する方法 |
| CN109182292B (zh) * | 2018-09-25 | 2022-02-08 | 安徽农业大学 | 一种草莓谷胱甘肽转移酶FaGST基因及其表达蛋白和应用 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004022738A1 (en) * | 2002-09-09 | 2004-03-18 | California Institute Of Technology | Methods and compositions for the generation of humanized mice |
| WO2006064197A2 (en) * | 2004-12-13 | 2006-06-22 | Iti Scotland Limited | Transgenic animals for assessing drug metabolism and toxicity |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1206906A4 (en) | 1999-08-13 | 2004-12-29 | Kirin Brewery | MOUSE CONTAINING A HUMAN P450 CYTOCHROME |
| EP1088900A1 (en) | 1999-09-10 | 2001-04-04 | Epidauros Biotechnologie AG | Polymorphisms in the human CYP3A4, CYP3A7 and hPXR genes and their use in diagnostic and therapeutic applications |
| CA2426959C (en) | 2000-11-01 | 2011-10-04 | The University Of Sydney | Transgenic animals for analysing cyp3a4 cytochrome p450 gene regulation |
| AUPR446701A0 (en) | 2001-04-18 | 2001-05-17 | Gene Stream Pty Ltd | Transgenic mammals for pharmacological and toxicological studies |
| JP2003304896A (ja) | 2002-04-15 | 2003-10-28 | Yasushi Yamazoe | ヒトｃｙｐ３ａ誘導能の測定法 |
| GB0216203D0 (en) | 2002-07-12 | 2002-08-21 | Imp Cancer Res Tech | Mondulation of cytochrome P450 reductase activity |
| US7759541B2 (en) * | 2004-12-13 | 2010-07-20 | Iti Life Sciences | Transgenic animals for assessing drug metabolism and toxicity |
-
2007
- 2007-06-04 US US11/757,972 patent/US7759541B2/en not_active Expired - Fee Related
-
2008
- 2008-06-04 WO PCT/GB2008/001897 patent/WO2008149080A1/en not_active Ceased
- 2008-06-04 US US12/602,723 patent/US8624079B2/en not_active Expired - Fee Related
- 2008-06-04 IN IN7390DEN2009 patent/IN2009DN07390A/en unknown
- 2008-06-04 JP JP2010510871A patent/JP2010528644A/ja active Pending
- 2008-06-04 AU AU2008259618A patent/AU2008259618A1/en not_active Abandoned
- 2008-06-04 CA CA002688438A patent/CA2688438A1/en not_active Abandoned
- 2008-06-04 EP EP08762250A patent/EP2173160A1/en not_active Withdrawn
-
2009
- 2009-11-15 IL IL202127A patent/IL202127A0/en unknown
-
2010
- 2010-05-26 US US12/787,816 patent/US8212105B2/en not_active Expired - Lifetime
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004022738A1 (en) * | 2002-09-09 | 2004-03-18 | California Institute Of Technology | Methods and compositions for the generation of humanized mice |
| WO2006064197A2 (en) * | 2004-12-13 | 2006-06-22 | Iti Scotland Limited | Transgenic animals for assessing drug metabolism and toxicity |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2014526932A (ja) * | 2011-08-26 | 2014-10-09 | オレア メディカル エスアエス | 動脈／組織／静脈の動態系の注目量を推定するシステムおよび方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| US20080148416A1 (en) | 2008-06-19 |
| US8212105B2 (en) | 2012-07-03 |
| EP2173160A1 (en) | 2010-04-14 |
| US20100257620A1 (en) | 2010-10-07 |
| IL202127A0 (en) | 2010-06-16 |
| IN2009DN07390A (enExample) | 2015-07-24 |
| US20100235928A1 (en) | 2010-09-16 |
| AU2008259618A1 (en) | 2008-12-11 |
| CA2688438A1 (en) | 2008-12-11 |
| US8624079B2 (en) | 2014-01-07 |
| WO2008149080A1 (en) | 2008-12-11 |
| US7759541B2 (en) | 2010-07-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010528644A (ja) | 薬物の代謝及び毒性を評価するためのトランスジェニック動物 | |
| Scheer et al. | Generation and characterization of novel cytochrome P450 Cyp2c gene cluster knockout and CYP2C9 humanized mouse lines | |
| Wu et al. | Conditional knockout of the mouse NADPH‐cytochrome p450 reductase gene | |
| KR20040015711A (ko) | 약물학적 및 독성학적 연구용 트랜스제닉 비인간 동물 | |
| JP2022065020A (ja) | Ｐ４５０オキシドレダクターゼ欠損を有するヒト肝臓キメラ非ヒト動物およびそれを使用する方法 | |
| CA2699547A1 (en) | Two step cluster deletion and humanisation | |
| EP1827087B1 (en) | Transgenic animals for assessing drug metabolism and toxicity | |
| EP2215240A1 (en) | Knockout mice for a p450 gene cluster | |
| Ward et al. | Comparative genomics reveals functional transcriptional control sequences in the Prop1 gene | |
| Lahiri et al. | Nephropathy and defective spermatogenesis in mice transgenic for a single isoform of the Wilms' tumour suppressor protein, WT1− KTS, together with one disrupted Wt1 Allele | |
| US20200085021A1 (en) | Model system for mitochondrial dysfunction and methods of using the same | |
| JP2011512834A (ja) | 非遺伝毒性発癌物質に関するスクリーニング | |
| HK1102391B (en) | Transgenic animals for assessing drug metabolism and toxicity | |
| WO2024052686A1 (en) | Immunodeficient non-human animals for assessing drug metabolism and toxicity | |
| Class et al. | Patent application title: SCREENING FOR NON-GENOTOXIC CARCINOGENS Inventors: Charles Roland Wolf (Dundee, GB) Clifford Roy Elcombe (Dundee, GB) Assignees: ITI SCOTLAND LIMITED | |
| Peters | Use of transgenic and knockout mice to study gene regulation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110524 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20110524 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20130514 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20130809 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20130816 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20140107 |